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Abstract
Background: Hyperlipidemia, a major pathological condition associated with disrupted lipid levels and
physiological redox homeostasis. The excessive release of reactive oxygen species (ROS) leads to enhanced
lipid peroxidation, aggravated atherosclerosis and oxidative stress. Integration of natural antioxidant blends in alone or
with conventional treatments can alleviate these issues synergistically contributing least side effects. Published
literature reported the efficacy of natural antioxidants as individual and in combinations in various conditions but less
data is available on their evaluation in low dose ratio blends particularly in hypercholesterolemic diet.
Methods: Antihyperlipidemic effects of selected natural antioxidants; the phenolic oligomeric proanthocyanidins
(OPC) and pterostilbene (PT) with niacin (NA) were investigated in current study. Their effects on lipid profile, lipid
peroxidation and their aptitude to establish redox state between oxidants and antioxidants in body were evaluated
in high cholesterol diet fed animal model. Male albino rabbits (n = 6) weighing 1.2–1.6 kg, supplemented with high
cholesterol diet (400 mg/kg) for 12 weeks were used in the experiment. Antioxidants were administered individual
high (100 mg/kg) and in low dose combinations (total dose = 100 mg/kg). Student’s t test and one way analysis of
variance (ANOVA) followed by Dunnet’s test were used as statistical tools for evaluation.
Results: The results showed synergistic effects of low dose antioxidant blends. Therapies retarded elevation in blood
lipid levels, lipid peroxidation and blood antioxidant depletion and consequently contributed in reestablishing redox
homeostasis. The LDL/HDL ratio and atherogenic index were suppressed significantly in blend therapies with
maximum effects of 59.3 and 25 % (p >0.001) observed in 50:30:20 ratios of OPC, NA and PT, compared to
individual therapies 37 and 18 % max respectively. Moreover the results were also in close proximity with the
statin therapy (52.66, 26.28 %).
Conclusion: This study provides an evidence for natural antioxidants blends superiority over individual
therapy in chronic diseases like hyperlipidemia. Such therapies in human equivalent doses can help in
mitigating chronic illnesses in general populations.
Keywords: Hyperlipidemia, Atherosclerosis, Redox homeostasis, Synergism, Lipid peroxidation
* Correspondence: jamshaidkhan@upesh.edu.pk
Department of Pharmacy, University of Peshawar, Peshawar 25120, Khyber
Pakhtunkhwa, Pakistan
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hannan et al. Lipids in Health and Disease  (2016) 15:151 
DOI 10.1186/s12944-016-0323-3
Background
Hyperlipidemia is a major pathological condition associ-
ated with mortality and disability in both developed and
developing countries [1]. Chronic diseases like obesity,
diabetes, atherosclerosis, coronary heart disease are
closely interconnected to hyperlipidemia. Intake of high
fat diet and lack of exercise are the major causes of
hyperlipidemia. In normal metabolic processes; reactive
oxygen species (ROS) are released as byproducts. They
act not only as essential part of immunity, in signaling
transduction and other vital processes but also respon-
sible for detrimental effects through peroxidation of lipid
bilayers. Therefore to maintain the physiological redox
environment, the excess radicals are get scavenged by
blood antioxidants [2]. Hyperlipidemia disrupts this
redox balance and cause abnormal and uncontrolled re-
lease of free radicals resulting in accelerated atherogenic
events developing a state of oxidative stress [3]. Endo-
thelial cell membrane and unsaturated lipids including
trans fatty acids is the main content of circulating low
density lipoproteins (LDL) are the most vulnerable sites
for free radical attack. Their oxidation leads to severe
endothelial cell injury and atherosclerosis [4–6]. The sat-
urated fats do not undergo lipid peroxidation therefore
has no direct effect on oxidative stress biomarkers [7].
However when esterified with poly unsaturated fatty
acids (PUFA), which is the readily oxidizable content,
the esters gets oxidized initiating the inflammation and
atherogenesis [8]. The antioxidants present in blo od
and organs including glutathione, ascorbic acid, α-
tocopherol fights against the progression of oxidative
stress to regain the redox homeostasis but gets depleted
in chronic conditions like hyperlipidemia [9, 10]. In such
circumstances interventions with natural antioxidants
supplements were found effective in normalizing lipid
profile and blood antioxidant levels as reported previ-
ously [4, 11, 12]. Research data is well documented and
supported the notion regarding their efficacies in
chronic pathologies such as hyperlipidemia [13–16].
Natural antioxidants were evaluated in individual and
in combinations for lipid lowering and free radical scav-
enging properties and were found effective in depressing
the disease progression [14–22]. In current study natural
antioxidants including oligomeric proanthocyanidins
(hydrophilic), pterostilbene (lipophilic) and niacin were
evaluated for extent of synergism by observing their
effects in both individual and blended therapies.
Oligomeric proanthocyanidins (OPC) is a polyphenolic
compound belongs to flavonoids class, widely distributed
in plants and posses potent antioxidant [23] and lipid mod-
ulatory effects [24, 25]. Pterostilbene (PT) a phytoalexin,
analogue of resvaretrol belong to the class stilbenes, found
in grapes majorly and possess antihyperlipidemic, antidia-
betic, antioxidant properties [26]. It is also a potent
activator of fatty acid metabolism [27]. Niacin or nicotinic
acid (NA) found in natural products and well known for
its antihyperlipidemic and antioxidant activities [28–30].
To best of our knowledge less data was extracted about
lipid lowering effect of pterostilbene with OPC and NA in
blend therapies especially low doses in orally fed high chol-
esterol diet models. The current study was designed to in-
vestigate the extent of synergism of selected hydrophilic/
lipophilic natural antioxidants in assorted combination
therapies in “hyperlipidemic animal model” using rabbits.
Antioxidants were administered in individual and in low
dose combination ratios. Atorvastatin was used as a stand-
ard for comparative analysis. Effects were evaluated against
negative control group kept on cholesterol only. Serum
lipid profiles were analyzed at predetermined intervals
using standard kit method, while blood antioxidants and
lipid peroxidation were evaluated using HPLC methods
[31, 32].
Results and discussions
Acute rise in lipid profiles were observed in rabbits
administered with cholesterol for 2 weeks compared to
healthy group. Almost two to four time rise was ob-
served in every parameter. Student’s t test was applied to
evaluate the difference statistically. Lipid profiles are cal-
culated as mean ± SEM (n = 6) along with p-values in
Table 1.
Effect of exogenous antioxidant therapy on serum lipid
profile
Single drug therapies showed significant effects in redu-
cing lipid levels, confirmed by LDL/HDL ratio and
atherogenic index (AI). The OPC, NA and PT main-
tained LDL/HDL ratios by 19.49 ± 0.87 (p <0.001), 20.26
± 0.94 (p <0.001) and 19.19 ± 0.91 (p <0.01) and AI
values 0.893 ± 0.033 (p <0.01), 0.896 ± 0.053 (p <0.01),
0.971 ± 0.073 (p <0.05) respectively. The atorvastatin
therapy showed 14.0 ± 0.99 (p <0.001) and 0.785 ± 0.061
(p <0.001) compared to disease control 30.50 ± 0.69,
1.096 ± 0.040. In combination therapies the results were
even more significant and synergism were observed by
improving blood lipid profile depending on dose ratio in
particular combination. Among combinations of OPC
with NA the 70:30 ratio delivered significant effects by
suppressing LDL/HDL ratio to 15.36 ± 0.98 (p <0.001)
while differ nonsignificantly from other two ratios 16.77
± 0.69 (p <0.001) and 17.33 ± 0.75 (p <0.001). AI was
significantly reduced to 0.843 ± 0.041 (p <0.001), 0.837 ±
0.045 (p <0.001) and 0.887 ± 0.037 (p <0.01) in 70:30,
30:70 and 50:50 respectively. Similarly in OPC with PT
combinations all the ratios provided significant effects
compared to disease control but no significant differ-
ences were observed between the groups. The LDL/HDL
and AI were 14.60 ± 0.98 (p <0.001) and 0.851 ± 0.041
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(p <0.001) in 70:30 ratio, 15.19 ± 0.42 (p <0.001), 0.929 ±
0.057 (p <0.05) in 30:70 and 16.33 ± 0.75 (p <0.001), 0.906
± 0.037 (p <0.01) in 50:50 respectively. In NA and PT, the
70:30 and 50:50 combinations induced similar effects on
LDL/HDL ratios 15.16 ± 0.89 and 15.16 ± 0.84 (p <0.001)
respectively, while comparing AI values results were more
profound in 70:30 (0.858 ± 0.053) (p <0.001) compared to
other groups 0.919 ± 0.037 (p <0.05) and 0.868 ± 0.037
(p <0.01) respectively. In general the two drug combi-
nations showed synergism, evident from significant
outcome however differ less from one another [33].
The ratios with optimum lipid lowering effects in
above therapies were subsequently molded in to three
drug combinations to evaluate the extent of synergism
of antioxidants acting through various mechanisms. The
antioxidant with highest ratio (70 %) was reduced by
20 mg and this amount was replaced with third candi-
date. All three drug combinations showed more signifi-
cant results as compared to two drug combinations.
Most significant effects were observed in 50:30:20 ratio
of OPC, NA and PT which suppressed LDL/HDL ratio
by 59.3 % and AI by 25 % (p <0.001) comparable with
the statin outcome 52.66, 26.28 % (p <0.001) respect-
ively. Though there were minor differences among the
groups but differ significantly from the disease con-
trol. The high dose single drug therapies suppressed
LDL/HDL by 37 % and AI by 18.5 % maximum,
which are much less as compared to low dose blend
therapies confirmed the superiority of combinational
therapies. Lipid profiles in mean ± SEM and %change
in blood lipids at 95 % confidence interval are sum-
marized in Tables 2 and 3.
Effect of exogenous antioxidant therapy on blood
endogenous antioxidants
Effects of natural antioxidants therapies on blood antiox-
idants were evaluated by quantifying their levels in
serum samples. They were quantified in normal, disease
control, statin group, individual therapies groups, com-
bination groups in each two drug ratios with optimum
effects and all three drugs combinational therapies.
Results showed initial rise in various antioxidants after
2 weeks of cholesterol dosing, presumably due to the
over activation of antioxidant enzymes the catalase,
glutathione peroxidase, superoxide dismutase and
others; accelerating the production of GSH against
peroxides radicals. Only NAC was found in reduced
concentrations.
Significant up-regulation was observed in levels of me-
thionine, GSH and NAC upto 35.08 ± 1.60, 3.82 ± 0.47
and 4.21 ± 0.425 μmol/L (p <0.001 each) respectively in
combination therapies compared to disease control
19.30 ± 1.18, 3.01 ± 0.28 and 3.73 ± 0.412 μmol/L.
Although in individual therapies the raised levels of me-
thionine, GSH and NAC (24.73 ± 1.04 μmol/L (p <0.05),
3.38 ± 0.42 μmol/L (p <0.01) and 3.86 ± 0.404 μmol/L (p
<0.05)) were less significant compared to combination
therapies. The all-trans retinoic acid showed opposite
results and increased parallel with the lipid levels from
1.80 ± 0.10 μmol/L (blank control) to 4.48 ± 0.24 μmol/L
(disease control) while in treatment groups its elevation
was retarded down to 3.26 ± 0.12 μmol/L (p <0.001)
max; observed on 70:30 ratio of OPC and PT.
The improvement in GSH/GSSG ratios was significant
in OPC (2.83 ± 0.065) (p <0.01) among individual ther-
apies and more in combinational therapies ranging 2.51
± 0.092 to 3.40 ± 0.097 (p <0.001), compared to disease
control 2.12 ± 0.058. Homocysteine level was signifi-
cantly controlled down to 10.09 ± 1.39 μmol/L (p <0.01),
although nonsignificant variations were observed among
treatment groups. Almost half of groups delivered non-
significant effects on ascorbic acid levels with maximum
effect of 5.29 ± 0.51 μmol/L (p <0.001) observed in
50:30:20 ratio of OPC, NA and PT compared to disease
control 4.90 ± 0.59 μmol/L. The natural antioxidants
were able to correct the antioxidant levels in blood and
are more effective when used in blend therapies rather
than individual as summarized in mean ± SEM in
Tables 4 and 5.
Discussions
Enhanced lipid peroxidation and endogenous antioxi-
dant depletion are undoubtedly associated with hyper-
lipidemia [10, 34, 35]. This leads to a number of
atherogenic effects including plaque formation in the
vessel lumen and accelerating foam cells formation
within vessel walls [36]. Natural antioxidants including
those used in current study were applied in many
chronic pathological conditions such as hyperlipid-
emia to prevent peroxidation, endogenous antioxidant
depletion and suppression of oxidative stress
Table 1 Lipid profiles of healthy and hypercholesterolemic
animals







Total cholesterol (mg/dl) 61 ± 2.468 249 ± 7.425 <0.0001
Triglycerides (mg/dl) 67 ± 0.635 140 ± 2.465 <0.0001
LDL-Cholesterol (mg/dl) 16.36 ± 0.618 172.3 ± 5.557 <0.0001
HDL-Cholesterol (mg/dl) 31.24 ± 1.241 48.72 ± 2.211 <0.0001
VLDL-Cholesterol (mg/dl) 30.45 ± 1.002 63.64 ± 2.113 <0.0001
LDL/HDL ratio 0.524 ± 0.035 3.536 ± 0.040 <0.0001
Atherogenic Index (AI) 0.331 (0.014) 0.458 (0.040) 0.0071
p-values acquired using student’s t test between columns
SEM standard error of mean
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progression [37, 38]. Natural antioxidants specially
polyphenols present efficacy up to certain level [39,
40] above which they were found ineffective or as pro-
oxidant by revoking their own beneficial effects. Similar
effects were observed in ascorbic acid interventions, pre-
venting pro-oxidant effects of LDL-associated α-
tocopherol when gets oxidized in blood [41]. Same initia-
tive was considered here that in place of using bulk dose
individual therapies, the low dose combination therapies
might provide superior results. Since each candidate de-
liver different antiperoxidative mechanisms preventing de-
pletion of antioxidant cofactors. OPC act by up-regulating
cytochrome (CYP) 7A1 enzyme induced bile secretion
[24], lipid intestinal absorption inhibition and very low
density lipoproteins (VLDL) secretion by liver [25]. PT
work through up-regulating peroxisome proliferator-
activated receptor (PPAR) [26]. NA by preventing lipid
mobilization from tissues and consequent rise in plasma
TG and free fatty acids (FFA) levels [29, 30, 42]. It also in-
creases the plasma HDL levels and act as antioxidant when
transformed into nicotinamide [28, 43–45]. To our know-
ledge no such extensive study was performed in hyperlipid-
emia to demonstrate dose dependant effect invivo in
combinational therapies of currently used antioxidants.
Our study revealed to be parallel with previous data
available on other disease conditions confirming the
hypothesis of enhancing efficacy of concurrently ad-
ministered natural antioxidants. Synergism at low
Table 2 Blood lipid profile of various groups after 12 weeks of study duration
Parameters
GROUP TC value (mg dl−1)
± SEM
LDL-C value
(mg dl−1) ± SEM
HDL-C value
(mg dl−1) ± SEM








1 Blank Control 105 ± 5.013 58.75 ± 18.25 30.65 ± 1.74 78 ± 3.527 35.45 ± 3.074 1.917 ± 0.56 0.406 ± 0.037









































































































































































































































For a group of six animals, the lipid profiles were calculated as mean ± SEM. Treatment groups were compared with the disease control using ANOVA followed by
Dunnet’s test (*p <0.05, ** p <0.01, ***p <0.001)
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Table 3 Mean percent change in lipid profile after 12 weeks in each treatment group
Parameters (%)
GROUP TC value (95 % CI) LDL-C value (95 % CI) HDL-C value (95 % CI) TG value (95 % CI) VLDL-C (95 % CI) LDL/HDL (95 % CI) Atherogenic index (95 % CI)
1 Atorvastatin −34.0 (−36.43, −31.57) −36.42 (−39.00, −33.80) 34.20 (29.78, 38.62) −30.80 (−32.74, −28.86) −30.80 (−33.58, −28.02) −52.66 (−62.56, −42.76) −26.28 (−31.97, −20.59)
2 Proanthocyanidins
(OPC)
−22.50 (−24.19, −20.81) −23.68 (−25.50, −21.86) 19.44 (16.30, 22.58) −25.07 (−27.33, −22.81) −25.05 (−26.18, −23.92) −36.09 (−40.21, −31.97) −18.52 (−20.26, −16.78)
3 Nicotinic acid (NA) −14.90 (−15.69, −14.11) −15.75 (−16.87, −14.63) 26.8 (23.19, 30.41) −19.88 (−21.48, −18.28) −19.85 (−21.78, −17.92) −33.57 (−37.57, −29.57) −18.25 (−21.03, −15.47)
4 Pterostilbene (PT) −26.22 (−27.59, −24.85) −28.47 (−30.51, −26.43) 13.69 (10.32, 17.06) −14.7 (−15.16, −14.24) −14.71 (−16.48, −12.94) −37.08 (−41.58, −32.58) −11.4 (−13.12, −9.679)
5 OPC : NA 30:70 −23.36 (−24.68, −22.04) −25.18 (−26.67, −23.69) 36.0 (31.41, 40.59) −25.07 (−26.62, −23.52) −25.05 (−27.19, −22.91) −45.02 (−49.82, −40.22) −23.63 (−26.88, −20.38)
6 OPC : NA 50:50 −25.58 (−26.81, −24.35) −27.66 (−29.11, −26.21) 27.27 (24.54, 30.00) −21.32 (−23.07, −19.57) −21.31 (−22.97, −19.65) −43.2 (−48.02, −38.38) −19.07 (−21.10, −17.04)
7 OPC : NA 70:30 −32.13 (−33.84, −30.42) −34.57 (−37.89, −31.25) 29.9 (25.39, 34.41) −27.4 (−29.81, −24.99) −27.4 (−29.48, −25.32) −49.64 (−57.83, −41.45) −23.08 (−25.94, −20.22)
8 OPC : PT 30:70 −36.79 (−39.00, −34.58) −40.17 (−42.27, −38.07) 20.09 (17.50, 22.68) −18.16 (−18.79, −17.53) −18.13 (−19.63, −16.63) −50.2 (−53.74, −46.66) −15.24 (−17.65, −12.83)
9 OPC : PT 50:50 −32.13 (−34.13, −30.13) −34.97 (−37.36, −32.58) 27.27 (22.98, 31.56) −21.33 (−23.07, −19.59) −21.31 (−22.97, −19.65) −48.9 (−54.96, −42.84) −19.07 (−21.11, −17.03)
10 OPC : PT 70:30 −35.73 (−38.01, −33.45) −38.97 (−41.34, −36.60) 27.45 (23.16, 31.74) −27.38 (−29.88, −24.88) −27.39 (−29.47, −25.31) −49.64 (−57.82, −41.46) −22.35 (−25.11, −19.59)
11 NA : PT 30:70 −34.99 (−37.18, −32.80) −38.0 (−39.77, −36.23) 20.05 (17.56, 17.56) −20.17 (−22.24, −18.10) −20.16 (−21.41, −18.91) −48.36 (−52.55, −44.17) −16.15 (−17.81, −14.49)
12 NA : PT 50:50 −31.71 (−33.47, −29.95) −34.57 (−36.54, −32.60) 31.62 (28.20, 35.04) −22.19 (−23.68, −20.70) −22.19 (−24.20, −20.18) −50.30 (−57.47, −43.13) −20.8 (−23.07, −18.53)
13 NA : PT 70:30 −30.34 (−29.62, −26.82) −33.13 (−32.21, −29.33) 34.53 (29.17, 39.89) −22.2 (−23.45, −20.95) −22.2 (−23.99, −20.41) −50.30 (−55.64, −41.48) −21.72 (−25.18, −18.26)
14 OPC : NA : PT
50:30:20
−40.49 (−42.95, −38.03) −44.1 (−46.86, −41.34) 37.26 (32.61, 41.91) −27.09 (−28.92, −25.26) −27.08 (−28.92, −25.24) −59.30 (−68.18, −50.42) −25.09 (−28.30, −21.88)
15 OPC : NA : PT
50:20:30
−39.53 (−41.86, −37.20) −43.13 (−45.10, −41.28) 32.5 (29.48, 35.52) −25.36 (−27.52, −23.20) −23.59 (−26.15, −21.03) −57.84 (−66.56, −49.12) −23.45 (−25.85, −21.05)
16 OPC : NA : PT
20:50:30
−37.80 (−39.74, −35.86) −41.4 (−44.20, −38.60) 38.99 (32.84, 45.14) −25.07 (−25.76, −24.38) −25.05 (−26.59, −23.51) −57.80 (−68.45, −47.15) −24.50 (−26.67, −22.33)
















combination doses amplifies the insight in reducing
the chances of antioxidants to become pro-oxidant.
The reduction in LDL/HDL ratio and AI validate the
positive outcome of multi antioxidant therapies on
lipid profile and blood antioxidants in hyperlipidemic
condition [39, 46–48].
The lipophilic antioxidant α-tocopherol, a major anti-
oxidant in LDL prevents peroxidation by getting oxidized
by free radicals and administering it alone especially in
chronic illnesses will increase cardiovascular risk rather
than decreasing it. Administration with exogenous antiox-
idants was found helpful in α-tocopherol regeneration
along with sparing other blood antioxidants from deple-
tion [32, 49]. Synergism was observed using plant phenolic
compounds with vitamin C in enhancing LDL resistance
towards oxidation [50]. Similarly in our results synergistic
effects were observed by combining phenolic compounds
with niacin confirmed by decelerated lipid peroxidation. It
is reported that use of single antioxidant cannot be able to
take the place of combination antioxidant therapy, since
giving a single drug in mega dose may behave like prooxi-
dant as observed in case of ascorbic acid [51], curcumin
[39] and other natural antioxidants thus may become
toxic rather that beneficial.
Similarly the antioxidant effect of catechin, hesperidin,
ferulic acid and quercetin were observed at low doses in-
dividually up to certain levels but became pro-oxidant as
the dose increased above that threshold level, while
combinations presented enhanced effects at various
doses [40]. This effect is due to the preventive behavior
for one another. The same proposal was focused in
current research to reduce the chances of single drug
dose bulking, system saturation and negative effects. A
study on oligomeric proanthocyanidins (OPC) reported
dose dependent results up to certain doses [52]. Simi-
larly in another study poor antihypertensive results were
obtained in high doses [53], may be due to pro-oxidant
effect [54] reducing its own activity. A parallel study on
pterostilbene and quercetin revealed significant results
in reducing lipid levels at lower doses but at higher
doses the effect was not as predicted indicating the
ceiling effect [55]. Niacin efficacy in combination with
conventional drug therapies and natural antioxidants are
already reported of providing synergistic effects on blood
Table 4 Quantification of water soluble endogenous antioxidants levels in various test groups
Parameters (μmol/L)




GSH/GSSG N- acetyl cysteine
Baseline 52.95 ± 1.68 13.66 ± 0.87 8.72 ± 0.87 38.05 ± 1.55 3.75 ± 0.384 0.87 ± 0.037 4.42 ± 0.085 4.57 ± 0.457
After 2 weeks of CHO-dosing 93.35 ± 3.81 14.31 ± 1.09 9.08 ± 0.96 34.97 ± 1.77 4.13 ± 0.245 1.25 ± 0.041 3.26 ± 0.067 4.38 ± 0.441
Observed changes after 90 days of treatment in groups
1 Blank control 60.37 ± 2.60 14.70 ± 1.49 8.56 ± 1.31 39.23 ± 1.88 3.78 ± 0.41 0.92 ± 0.029 4.18 ± 0.12 4.49 ± 0.429

































































































































































For a group of six animals, the lipid profiles were calculated as mean ± SEM. Treatment groups were compared with the disease control using ANOVA followed by
Dunnet’s test (*p <0.05, ** p <0.01, ***p <0.001)
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lipid profile and improving cardiovascular health in clin-
ical and preclinical studies [56, 57]. It acts dose depend-
ently up to large doses but, the chances of adverse
effects like hepatotoxicity [58] and hyperhomocyteineae-
mia [59] are also reported. However, if combined in low
doses with other drugs the adverse events can be mini-
mized along with maximized beneficial outcome. Our
proposed therapies were found parallel with several
other studies that utilized natural antioxidants in various
cardiovascular related conditions [5, 30, 35, 57–60].
Key findings of current study is that combination ther-
apies of natural antioxidants can provide synergistic and
additive support for normalizing lipid profile and blood
antioxidants in chronic pathological conditions if used
below ceiling line. Assessing the serum levels of bio-
compounds, the elevated levels of cystine, cysteine,
homocysteine, all-trans retinoic acid and malondialde-
hyde validated their involvement in development of
hyperlipidemia associated oxidative stress. We developed
a dose rationale of selected antioxidants in combination
for future use in human equivalent doses in which their
efficacies can be evaluated in uncontrolled dietary habits.
This will help in developing an efficacy based correlation
between preclinical and clinical outcome in preventing
atherosclerosis, comparable to conventional drug therap-
ies with negligible side effects.
Conclusion
In present study hypolipidemic and endogenous antioxi-
dant sparing effects of natural antioxidants were investi-
gated in cholesterol fed rabbits. Results supported the
assumption of synergism of natural/dietary antioxidants
in combination therapies in chronic ailments. Low dose
blend therapies were more effective than individual bulk
doses as depicted. We recommend antioxidants in com-
bination dose rationale for achieving maximum benefits
in long term therapies.
Methods
Chemicals, drugs and reagents
Pure cholesterol (Avonchem UK) (≥99 % pure). Choles-
terol kit; TC, TG and HDL (Human diagnostics GmbH
Germany). Oligomeric proanthocyanidins (OPC) (Shaanxi
Run-Time Bio-Technology Development Co., Ltd), pteros-
tilbene (PT) (Shanghai Korey Pharm Co., Ltd) (≥99 %
Table 5 Quantification of fat soluble endogenous antioxidants, ascorbic acid and malondialdehyde levels in various test groups
Parameters (μmol/L)
Group α-Tocopherol All-trans retinoic acid Ascorbic acid Malondialdehyde
Baseline 18.46 ± 1.74 1.83 ± 0.1143 5.59 ± 0.58 3.37 ± 0.233
After 2 weeks of CHO-dosing 17.29 ± 1.56 2.45 ± 0.1511 5.45 ± 0.67 4.08 ± 0.269
Observed changes after 90 days of treatment in groups
1 Blank control 18.87 ± 1.49 1.80 ± 0.10 5.53 ± 0.72 3.49 ± 0.318

















































































For a group of six animals, the lipid profiles were calculated as mean ± SEM. Treatment groups were compared with the disease control using ANOVA followed by
Dunnet’s test (*p <0.05, ** p <0.01, ***p <0.001)
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pure) and niacin (NA) (Scharlau Chemie SA) (≥98 %
pure).
Equipments
HPLC system (Perkin Elmer, Norwalk, USA) linked with
a DECADE II Electrochemical Detector (Antec Leyden,
Netherland), HPLC column Discovery HS C18 RP chro-
matographic column (250 mm× 4.6 mm, 5 μm; Belle-
fonte, USA). Lambda-25 UV/Visible spectrophotometer
(Perkin Elmer). Centrifuge machine (Centurion scientific
Ltd) and Incubator (Incucell Med Center GmbH
Germany) were used in the analysis.
Hyperlipidemic model development and interventional
protocol
Male Albino rabbits (1.2–1.6 kg body weight) were used
in the experiment. The experimental protocol for our
study was approved by ethical committee of Department
of Pharmacy University of Peshawar under reference
number: 04/EC-15/Pharm. After 7 days of acclimatization
in animal house and bio assay center, hyperlipidemia was
developed according to the previous reported protocol
[61]. Animals were administered 400 mg/kg cholesterol
suspension in 3 ml sunflower oil along with normal diet
(protein, fats and fibers each up to 12 %, carbohydrates
65 % and minerals 2–5 %) for about 2 weeks and subse-
quent analysis of serum samples. Animal having total
cholesterol level raised up to 200–250 mg/dl were selected
and divided into several groups of n = 6. Three groups
were treated with OPC, PT and NA individually in
100 mg/kg doses along with cholesterol doses. In 09
groups, low dose combinatorial blends of all the three
drugs in 30:70, 50:50 and 70:30 ratios were administered
and most effective combination in each two drug combi-
nations was further incorporated in three drug combina-
tions (Table 2). These blends were applied to determine
possible extent of synergism of low dose therapies in com-
parison with individual high dose (100 mg/kg) drug ther-
apy. Atorvastatin (1 mg/kg) was used as standard in group
III [62], group I was kept at baseline (saline) and group II
on cholesterol only. Duration of therapy was 3 months;
the animals were allowed free access to food and water ad
libitum. At the end of therapy blood samples were
collected in sufficient volumes for lipid profile and chro-
matographic analysis.
Laboratory analysis
Plasma lipid profiling was performed on commercial
kits. Base line levels were recorded and samples were
taken at every 2 weeks interval after overnight fasting to
evaluate the effect of therapies on blood lipid levels
sequentially. Total cholesterol (TC), teiglyceride (TG)
and high density lipoproteins (HDL-C) were calculated
enzymatically, while low density lipoproteins (LDL-C),
very low density lipoproteins (VLDL-C) and atherogenic








AI ¼ Log TG=HDL‐Cð Þ ð3Þ
Serum levels of water soluble thiol antioxidants; glutathi-
one (GSH) its oxidized form (GSSG), GSH/GSSG ratio,
cystine, cysteine (cys), Homocysteine (Hcy), methionine
(meth), N-acetylcysteine (NAC) long with ascorbic acid
(AA) and lipid peroxidation were determined simultan-
eously at the end of study using RP-HPLC- electro chem-
ical detection (ECD) method [31]. Fat soluble antioxidants;
α-tocopherol (α-TOH) and all-trans retinol (ATR) were
determined simultaneously using HPLC-UV [32].
Statistical analysis
Data analysis was performed by applying student’s t test
for pair analysis and one way analysis of variance
(ANOVA) followed by Dunnett’s test for comparison of
lipid lowering effect in all treatment groups with respect
to the disease control (with no treatment). Data is pre-
sented in mean ± standard error of mean (SEM) at level
of significance p <0.05 %.
Abbreviations
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